14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.87 $1.65 Wednesday, 24th Apr 2024 ADAP stock ended at $1.08. This is 5.26% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 7.48% from a day low at $1.07 to a day high of $1.15.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Sep 18, 2023 $0.784 $0.790 $0.740 $0.741 404 174
Sep 15, 2023 $0.735 $0.82 $0.735 $0.81 769 830
Sep 14, 2023 $0.83 $0.85 $0.777 $0.81 498 261
Sep 13, 2023 $0.770 $0.82 $0.766 $0.80 153 647
Sep 12, 2023 $0.795 $0.83 $0.766 $0.768 483 542
Sep 11, 2023 $0.735 $0.81 $0.735 $0.80 675 932
Sep 08, 2023 $0.759 $0.759 $0.735 $0.735 463 123
Sep 07, 2023 $0.755 $0.766 $0.745 $0.765 515 335
Sep 06, 2023 $0.776 $0.780 $0.755 $0.760 643 152
Sep 05, 2023 $0.780 $0.795 $0.776 $0.776 308 496
Sep 01, 2023 $0.781 $0.81 $0.775 $0.790 188 367
Aug 31, 2023 $0.81 $0.82 $0.780 $0.780 162 328
Aug 30, 2023 $0.80 $0.83 $0.785 $0.82 287 453
Aug 29, 2023 $0.780 $0.82 $0.780 $0.80 172 190
Aug 28, 2023 $0.80 $0.83 $0.780 $0.780 67 073
Aug 25, 2023 $0.795 $0.83 $0.775 $0.780 701 123
Aug 24, 2023 $0.81 $0.85 $0.795 $0.80 522 670
Aug 23, 2023 $0.790 $0.84 $0.790 $0.82 645 153
Aug 22, 2023 $0.80 $0.81 $0.785 $0.787 230 746
Aug 21, 2023 $0.799 $0.82 $0.772 $0.80 319 053
Aug 18, 2023 $0.799 $0.84 $0.784 $0.784 171 535
Aug 17, 2023 $0.787 $0.83 $0.770 $0.82 443 175
Aug 16, 2023 $0.775 $0.790 $0.770 $0.777 345 636
Aug 15, 2023 $0.775 $0.799 $0.775 $0.780 335 253
Aug 14, 2023 $0.81 $0.82 $0.773 $0.785 691 995
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT